ChuánKǎi Chéng 程傳凱

"aHoi" is how "ah-凱(Kai)" pronounced in Cantonese; student from SAR11 growth physiology

[ChuánKǎi Chéng 程傳凱 @aHoi_Ching]

It is official now! 🥳

[Cameron Thrash @jcamthrash]

Our latest. Led by the very talented @aHoi_Ching

Cell cycle dysregulation of globally important SAR11 bacteria resulting from environmental perturbation https://t.co/MkYCRNnXDi

[Cameron Thrash @jcamthrash]

Multi-omic data fusion reveals the in vivo enzyme kinetics of Vibrio natriegens at the genome-scale https://t.co/dE8s10E9Gt

[Nicholas Hornstein @GIMedOnc]

#ASCO26

This one is special.

This is the hottest paper of 2026 and potentially in the history of pancreatic cancer.

Let’s dive in.

RASolute 302: Daraxonrasib vs investigator’s choice chemotherapy in previously treated metastatic pancreatic cancer
Abstract LBA5 (soon!)
Presentation: May 31, 2026, 3:21-3:33 PM CDT

For decades, pancreatic cancer has been where good ideas go to die.

We have optimized chemotherapy. We have sequenced chemotherapy. We have celebrated modest gains.

But the central driver of PDAC has always been sitting there in plain sight:

RAS.

More than 90% of pancreatic cancers have oncogenic RAS mutations, and until recently, we had essentially nothing direct to do about it.

Daraxonrasib is an oral RAS(ON) multiselective inhibitor targeting the active GTP-bound state of mutant and wild-type RAS.

And in RASolute 302, it delivered.

Quick hits:

📌 Phase 3 international randomized trial 500 patients with previously treated mPDAC Daraxonrasib vs investigator’s choice chemotherapy

🧬 RAS G12 population
91.8% of patients had RAS G12 mutations

📈 OS in RAS G12 population
13.2 vs 6.6 months
HR 0.40
P<0.001

📈 OS in overall population
13.2 vs 6.7 months
HR 0.40
P<0.001

📊 PFS in RAS G12 population
7.3 vs 3.5 months
HR 0.45
P<0.001

📊 PFS in overall population
7.2 vs 3.6 months
HR 0.49
P<0.001

🔥 12-month OS
Overall population: 53.2% vs 17.3%

⚠️ Toxicity matters, but this was not just more efficacy for more toxicity
Grade ≥3 AEs: 61.8% vs 69.6%
TRAEs leading to discontinuation: 1.2% vs 11.2%

This is the kind of survival curve we almost never get to see in pancreatic cancer.

This validates RAS(ON) inhibition in the most RAS-addicted major cancer. It takes a target we have talked about for decades and turns it into a clinically meaningful survival benefit in a randomized phase 3 trial.

The next questions come fast: 1L combinations, maintenance, perioperative disease, sequencing, resistance, toxicity management, and whether this becomes a new backbone.

RAS is here, and it couldn’t have come sooner.

https://t.co/Y4WJRlRRTk

@TheGutonclab @UGrewalMD @TimothyJBrownMD @OncoAlert @Onco_Nexus @ASCO
@NazliDizman @LauraAlderMD @DVAraujoMD @DrBarbiOnc @LauraEsfeller @FunchainMD @YGaritaonaindia @DrSAHaddad @jgong15 @iandresmeraz @SakditadMD @RamilaShilpakar @RohitBanwar @lungoncdoc

[Patrick Hsu @pdhsu]

people aren’t celebrating this pancreatic cancer breakthrough enough. it should be international news

[PriME - Principles of Microbial Ecosystems @PriME_SimFdn]

❓Can we predict ocean carbon cycling by looking at what microbes do rather than who they are?🌊

During his PhD in PriME, Ryan Reynolds explored this question by combining global metagenomic with metabolic modeling 😀

Check out his last publication 👇
https://t.co/Ao2tRpHh5a

[Cameron Thrash @jcamthrash]

Marine microbiomes and their expanding role in biotechnological potential: a systematic review https://t.co/VzchKSZp6g

[Nathan Lewis @Nathan_E_Lewis]

Why do some cells produce more protein than others? Jasmine Tat (UCSD &amp; Amgen) conducted a detailed study into the single-cell transcriptome, while measuring mAb production in single cells too with SEC-seq. Check out the preprint! https://t.co/Mjv2Y5JI0H

[ChuánKǎi Chéng 程傳凱 @aHoi_Ching]

@nkjmu Yay thanks Yu! Looking forward to more bacteriorhodopsin work from you!🙌🙌🙌🙌

[ChuánKǎi Chéng 程傳凱 @aHoi_Ching]

It is official now! 🥳

[Cameron Thrash @jcamthrash]

Our latest. Led by the very talented @aHoi_Ching

Cell cycle dysregulation of globally important SAR11 bacteria resulting from environmental perturbation https://t.co/MkYCRNnXDi

[Saligrama lab_WUSTL @SaligramaLab]

House Appropriations minibus bill funding #NIH is out now.
- $400M increase
- Multiyear funding of new awards capped at 2025 levels.
- No line item for #BRAIN #Initiative

text here: https://t.co/6pmcDY1iUw

[ASM @ASMicrobiology]

How did life begin, and why does it matter? Scientists are tracing early microbial life–from LUCA to multicellularity–to unlock insights for biotech, climate science and even space exploration. Read the article: https://t.co/I5jhucISdS

[Cameron Thrash @jcamthrash]

Do you like coastal/estuarine microbiology, time-series data, and/or metagenomics? Have we got a dataset for you #NSFfunded

Metagenomes and 1,313 metagenome-assembled genomes from a northern Gulf of Mexico coastal time series https://t.co/rofnYYpevF

[Miaoxiao Wang (Roy) @MiaoxiaoR]

Excited to share our new work in @PNASNews on microbial mutualism!
We show how degraders &amp; nondegraders collaborate to stabilize biopolymer-degrading communities — with powerful applications in microbiome engineering.

Proud to be part of this work!
👉 https://t.co/a6I3yB2wJo

[ChuánKǎi Chéng 程傳凱 @aHoi_Ching]

@nkjmu It’s amazing that the report look so formal (with a DOI)!

[ChuánKǎi Chéng 程傳凱 @aHoi_Ching]

本当にありがとうございます!

https://t.co/FiGkGiX27k

[Yu Nakajima @nkjmu]

GRS/GRCでルームメイトだったChuanKai氏のSAR11論文だ！

&gt;RP

[ChuánKǎi Chéng 程傳凱 @aHoi_Ching]

@nkjmu Haha I am flattered! Thank you so much Yu!

[ChuánKǎi Chéng 程傳凱 @aHoi_Ching]

I will be giving a talk at #ASMicrobe this afternoon! Looking forward to chatting with y’all!❤️

[Cameron Thrash @jcamthrash]

Chuankai Cheng @aHoi_Ching Saturday EEB-IDS-305 402AB, LACC
Disruption of SAR11 Cell Cycle Through Excessive Nutrient Perturbation Reveals the Connections Between Genome Streamlining and Obligate Slow Growth
3-3:15

(3/4)... one more -&gt;

[ChuánKǎi Chéng 程傳凱 @aHoi_Ching]

One of the fun things to do at #ASMicrobe is to greet and chat with @markowenmartin !

[ChuánKǎi Chéng 程傳凱 @aHoi_Ching]

🎉🎉🎉

[Cameron Thrash @jcamthrash]

Our latest on the microbiology of SAR116, led by the indefatigable Jordan Coelho:

Culture-supported ecophysiology of the SAR116 clade demonstrates metabolic and spatial niche partitioning https://t.co/Zjoqp8vTxK

[Cameron Thrash @jcamthrash]

Our latest on the microbiology of SAR116, led by the indefatigable Jordan Coelho:

Culture-supported ecophysiology of the SAR116 clade demonstrates metabolic and spatial niche partitioning https://t.co/Zjoqp8vTxK

[Noelle A. Held @proteocean]

I am hiring a research/technical specialist/manager to help us make the most out of new LC-MS instrumentation at USC! Please share the word and write me for more details. https://t.co/7vS22pvmic...